Effector Therapeutics is partnering with Pfizer and Merck to evaluate two immuno-oncology agents in patients with microsatellite stable colorectal cancer.
Here's what you should know:
1. The companies are going to conduct a phase II, open-label, randomized, non-comparative study to examine Effector's small molecule MNK1/2 inhibitor eFT508 — a cancer treatment that uses the body's immune system to fight cancer.
2. The inhibitor will be paired with avelumab in patients with relapsed or refractory CRC. The companies will also evaluate eFT508 alone as a monotherapy.
3. Researchers will randomize patients two-to-one into combo-and monotherapy arms.
4. The companies will begin the study in the third quarter of fiscal year 2017.